[This Week's IPO] Book-Building and Subscription Schedule for the Fourth Week of March

During the fourth week of this month (March), Hana Office REITs will conduct a book-building process for institutional investors. Inventera is preparing for a public subscription for retail investors.

<Book-building>

◆Hana Office REITs= The assets of this REIT consist of the Hana Financial Group Gangnam Office Building and the Taekwang Tower. These properties are located in the GBD (Gangnam Business District) core area, just a three-minute walk from Gangnam Station and Yeoksam Station. Gangnam is a major business hub in Seoul, where global corporations and large domestic companies have their headquarters. In particular, the Teheran-ro area is considered a prime location with limited new office supply.

The offer price is set at 5,000 won per share, with a total of 25.2 million shares offered. The company aims to raise 12.6 billion won through this offering. Book-building for domestic and overseas institutional investors will take place over two days, from March 23 to 24, and the public subscription for retail investors will be held over two days, from March 31 to April 1. The listing on the KOSPI market is scheduled for April. Hana Securities and Korea Investment & Securities are the joint lead underwriters for this offering.

<Public Subscription>

◆Inventera= The final offer price has been set at 16,600 won per share, at the top end of the indicative price range. A total of 2,309 institutional investors participated in the book-building, resulting in a competition ratio of 1,328.82 to 1. The public subscription for retail investors will be held from March 23 to 24, with a target listing on the KOSDAQ market in early April. NH Investment & Securities is the lead underwriter, and Eugene Investment & Securities is the joint underwriter.

Inventera's Invinity™ is a nanostructure platform that addresses two major challenges in the field of nanomedicine: the protein corona phenomenon and the problem of 'immune cell phagocytosis' caused by low dispersion stability. Based on this technology, the company is prioritizing the commercialization of a novel disease-specific nano-MRI contrast agent and is also working to expand into the therapeutic drug sector.

This content was produced with the assistance of AI translation services.